Rege Nephro Co., Ltd. (Headquarters: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) is pleased to announce that it has entered into a collaborative research agreement with Roche (Headquarters: Basel, Switzerland), for drug discovery using an iPS cell-derived disease model.

Rege Nephro is advancing iPS cell-based drug discovery using human disease models derived from iPS cells, focusing primarily on the renal genetic disorders. As an example, in 2024 we initiated Phase 2 clinical trials for RN-014, which was identified from our iPS cell-derived human ADPKD model.

Through this collaborative research, both corporations will collaborate to accelerate the development of novel therapeutics for rare genetic diseases and contribute new value to society.

Media Inquiries:
Katsuhisa Yamaguchi, CFO
Rege Nephro Co., Ltd.
TEL: 075-744-6858
E-mail: info@regenephro.co.jp